Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials

2728 results

Sort By:

Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care

Study ID: NCT07169422
Start Date: 2026-01
End Date: 2028-07
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

120

Intervention / Treatment

Usual care for diabetic kidney disease management without primary care provider.

Pharmacist-led validated diabetic kidney disease decision support algorithm.

Sponsor

Nova Scotia Health Authority

Source: clinicaltrials.gov

Share:
Add to list

A Clinical Trial to Investigate Efficacy, Safety and Pharmacokinetics (PK) of Two LXE408 Oral Regimens and Oral Miltefosine as Active Control in Participants Aged ≥ 18 Years Old With Localized Cutaneous Leishmaniasis in the Region of the Americas (AMR).

Study ID: NCT06997159
Start Date: 2025-11-16
End Date: 2027-07-10
Study Type

Interventional

Study Phase

Phase2

No. of Participants

250

Intervention / Treatment

LXE408

Miltefosine 50 MG Oral Capsule [Fearless]

Placebo to LXE408

Sponsor

Drugs for Neglected Diseases

Source: clinicaltrials.gov

Share:
Add to list

Masitinib in Patients With Mild Alzheimer's Disease

Study ID: NCT05564169
Start Date: 2026-06
End Date: 2029-12
Study Type

Interventional

Study Phase

Phase3

No. of Participants

600

Intervention / Treatment

Placebo

Masitinib (4.5)

Standard of care

Sponsor

AB Science

Source: clinicaltrials.gov

Share:
Add to list

Efficacy of Tezepelumab in Peanut Oral Immunotherapy

Study ID: NCT07015996
Start Date: 2026-02-18
End Date: 2028-09-16
Study Type

Interventional

Study Phase

Phase2

No. of Participants

62

Intervention / Treatment

Tezepelumab

Peanut Oral Immunotherapy (OIT)

Placebo for Tezepelumab

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Source: clinicaltrials.gov

Share:
Add to list

Lower Limb ExoNET: Development and Evaluation for Gait Assistance With Stroke Survivors

Study ID: NCT06999213
Start Date: 2026-01-31
End Date: 2029-12-31
Study Type

Interventional

Study Phase

Early_phase1

No. of Participants

20

Intervention / Treatment

Assist

Resist

Slack

Sponsor

Shirley Ryan AbilityLab

Source: clinicaltrials.gov

Share:
Add to list

Social Groups for Autistic Young Adults (SDARIYA)

Study ID: NCT07222982
Start Date: 2026-01-15
End Date: 2031-02
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

54

Intervention / Treatment

GARDENS-I

AYA

Sponsor

Drexel University

Source: clinicaltrials.gov

Share:
Add to list

Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia

Study ID: NCT06802523
Start Date: 2026-04-21
End Date: 2028-12-31
Study Type

Interventional

Study Phase

Phase1

No. of Participants

53

Intervention / Treatment

Actinium and 225 Lintuzumab

Biospecimen Collection

Bone Marrow Aspiration

Bone Marrow Biopsy

Decitabine and Cedazuridine

Venetoclax

Sponsor

National Cancer Institute (NCI)

Source: clinicaltrials.gov

Share:
Add to list

Understanding How Cigarette Direct Mail Marketing Influences Smoking Behaviors Among High and Low Socioeconomic Status Young Adult Smokers

Study ID: NCT02974582
Start Date: 2026-10-17
End Date: 2027-10-06
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

530

Intervention / Treatment

Exposure to smoking advertising with coupon

Exposure to smoking advertising without coupons

Exposure to non health related images

Sponsor

National Institute on Minority Health and Health Disparities (NIMHD)

Source: clinicaltrials.gov

Share:
Add to list

Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder

Study ID: NCT07218354
Start Date: 2026-01-01
End Date: 2029-01-26
Study Type

Interventional

Study Phase

Phase3

No. of Participants

438

Intervention / Treatment

Semaglutide

Placebo

Sponsor

VA Office of Research and Development

Source: clinicaltrials.gov

Share:
Add to list

Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma

Study ID: NCT07223541
Start Date: 2025-12
End Date: 2031-08
Study Type

Interventional

Study Phase

Phase2

No. of Participants

72

Intervention / Treatment

Cemiplimab 350 MG Intravenous Solution

Fianlimab 1600 MG Intravenous Solution

Sponsor

University of Oklahoma

Source: clinicaltrials.gov

Share:
Add to list